Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with schizophrenia or schizoaffective disorder according to current psychiatric diagnostic standards (DSM-5)
- People between 18 and 50 years of age
- People who have been taking the medication clozapine for at least 4 months
- People who have previously tried at least 2 other antipsychotic medications that did not work well enough
- People who are mentally able and willing to sign a consent form agreeing to take part
- People who are on a stable, medically optimised dose of clozapine (at least 150 mg per day) that has not changed for at least 1 month
Who may not be able to join:
- People with a serious neurological or other medical condition, or who are receiving a treatment, that affects how the brain works
- People considered to be at significant risk of harming themselves or others
- People whose thinking, communication, or other factors would prevent them from being able to give informed consent
- People who are pregnant or who are within 6 weeks of giving birth or experiencing a miscarriage
- People who have previously been treated with electroconvulsive therapy (ECT)
- People who cannot safely have an MRI scan (for example, those with a pacemaker)
- People who have a moderate or severe substance use disorder, including alcohol use disorder, as confirmed through a structured clinical interview
- People who have a seizure disorder or who have had seizures while taking clozapine
- People who are currently taking both bupropion and clozapine at the same time
- People who have previously had problems with a specific type of brain stimulation treatment called intermittent theta burst stimulation or transcranial magnetic stimulation (confirm with trial site)
- People taking a class of medications called SNRIs (serotonin and norepinephrine reuptake inhibitors) — these cases will be considered individually by the trial team
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Deepak K Sarpal, M.D., University of Pittsburgh
Phone: 412-246-5618
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
change in brain functional connectivity within the prefrontal cortex; change in activation of the working memory network
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.